Orexigen Therapeutics Reduces Q4 Loss by 34%

Fat-fighting clinical-stage biopharmaceutical company Orexigen Therapeutics (NASDAQ: OREX  ) posted a narrower fourth-quarter loss on the back of lower research and development expenses.

For the quarter, Orexigen recorded $857,000 in revenue which is consistent with the year-ago quarter and based on its amortized collaborative revenue agreement with partner Takeda Pharmaceuticals (NASDAQOTH: TKPYY  ) from a deal logged in 2010.

Net loss, however, dipped 33.8% to $21.5 million, or $0.21 per share, from $32.5 million, or $0.41 per share, in the year-ago quarter. It is worth noting, though, that Orexigen has 22.8 million more shares outstanding now than it had at the end of this quarter last year.

Critical to Orexigen's narrower loss was a dramatic decrease in research and development expenses to $15.5 million from $28.3 million. This drop was attributed to the completion of the cardiovascular outcomes trial known as the Light Study for experimental weight-loss drug Contrave. General and administrative expenses actually rose 24.8% to $6.3 million.

Orexigen ended 2013 with $177 million in cash, cash equivalents, and marketable securities and forecast 2014 operating expenses in the $75 million-$85 million range. The company noted, though, that it anticipates its cash, cash equivalents, and marketable securities balance will be higher a year from now because it is eligible to receive a $100 million milestone payment from Takeda once Contrave is approved in the U.S. and logs its first commercial sale.

Finally, the press release notes CEO Michael Narachi's optimism that Contrave will be approved in the both the U.S. and European markets in 2014, and that the company expects to work on finding a partner to commercialize its weight control management drug outside of North America. 


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 13, 2014, at 8:50 AM, marp11 wrote:

    not bad 800k in revs

    80 million in expenses

    guess arna has the correct model for success

  • Report this Comment On March 13, 2014, at 8:52 AM, marp11 wrote:

    no pipeline 2 generic drugs no money huge expenses

    beyond laughable

    vvus failed soon orex

    come to arna we still have tons of room

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2873839, ~/Articles/ArticleHandler.aspx, 8/31/2014 6:43:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement